Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 116 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Follow-Up Questions
Olema Pharmaceuticals Inc のCEOは誰ですか?
Mr. Sean Bohen は Olema Pharmaceuticals Inc の President で、2020 から在籍しています。
OLMA の株価パフォーマンスは?
OLMA の現在の価格は $7.91 で、最終取引日から 1.43% decreased 変動しました。
Olema Pharmaceuticals Inc の主な事業テーマや業界は?
Olema Pharmaceuticals Inc は Biotechnology 業界、セクターは Health Care に属しています。